Drugs / Diacetylmorphine
Diacetylmorphine
also known as
Diamorphine · heroin · DAM · Diacetylmorphine hcl · Diacetylmorphine hydrochloride · Diacetylmorphine hydrochloride ci · Diamorphine hydrochloride · IDS-NH-001 · +3 more
Small molecule targets OPRM1 via activation
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT01760473 | May 2009 → Dec 2014 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT00175357 | Mar 2005 → Apr 2007 | opiate dependence | University of British Columbia | Completed | Met primary |
| Phase 3 | NCT00268814 | Mar 2002 → Dec 2003 | opiate dependence | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02210260 | Sep 2013 → Feb 2016 | colorectal cancer | York Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01174927 Comparator | Mar → Dec 2010 | opiate dependence | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 3 | NCT01447212 Comparator | Dec 2011 → Jun 2014 | heroin dependence | University of British Columbia | Completed | Mixed |
| Phase 3 | NCT00710385 Comparator | Sep 2007 → Aug 2008 | substance-related disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02009306 Background | Jan 2017 → Feb 2018 | — | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00880373 Comparator | Mar 2011 → Mar 2014 | sickle cell disease | London North West Healthcare NHS Trust | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01049672 Comparator | Sep 2010 → Nov 2014 | cancer | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diacetylmorphine | “BACKGROUND: Studies in Europe have suggested that injectable diacetylmorphine, the active ingredient in heroin, can be an effective adjunctive treatment for chronic, relapsing...” PMID 19692689 ↗ Aug 2009 |
| Known as | DAM | “BACKGROUND: The North American Opiate Medication Initiative (NAOMI) clinical trial compared the effectiveness of injectable diacetylmorphine (DAM) or hydromorphone (HDM) to...” PMID 25262567 ↗ Sep 2014 |
| Known as | Diacetylmorphine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Known as | Diacetylmorphine hydrochloride | “Diacetylmorphine hydrochloride (the active ingredient in heroin), delivered under supervision” PMID 27049826 ↗ May 2016 |
| Known as | Diacetylmorphine hydrochloride ci | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Known as | Diamorphine | “* Opioids for pain or dyspnoea * Diamorphine” NCT02009306 ↗ |
| Known as | Diamorphine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Known as | heroin | “Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine” NCT02033707 ↗3“Intranasal challenge drug: 24 mg of heroin administered intranasally.” NCT01760473 ↗ “injectable diacetylmorphine (DAM; heroin)” NCT01447212 ↗ |
| Known as | IDS-NH-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Known as | IDS-NH-001(SECT.3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Known as | J6.494G | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Known as | NSC-302357 | ChEMBL registry synonym — accepted as the source's own label CHEMBL459324 ↗ |
| Action | Activate | “The main objective of the NAOMI Study is to determine whether the closely supervised provision of injectable, pharmaceutical-grade opioid agonist is more effective than...” PMID 19159475 ↗ Jan 20091“Mu opioid receptor agonist” CHEMBL459324 ↗ |
| Modality | Small molecule | — CHEMBL459324 ↗ |
| Route | Other | “The injected drug will be administered up to 3 doses per day, 7 days per week.” NCT00175357 ↗ |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL459324 ↗ |